Abstract library

15 results for "Pontecorvi".
#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Giovanni Schinzari
#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#542 Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a neuroendocrine tumor board (TB) established at our University Hospital.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#543 Endoscopic Ultrasound-Guided Fine Needle Tissue Acquisition (EUS-FNTA) Using a 19-G Needle for Histological Grading of Pancreatic Endocrine Tumors (PETs): A Prospective Study
Introduction: EUS-FNTA is increasingly used in the diagnosis of pancreatic endocrine tumors (PETs). Ki-67 expression, an important prognostic factor according to the WHO classification, is difficult to be determined on cytological specimens.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
Authors: Larghi A, Fusco A, Bianchi A, Lugli F, ...
Keywords: EUS, Ki-67, grading, pancreas
#764 The Experience of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a Neuroendocrine Tumor Board established at our University Hospital.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Laura De Marinis
#765 Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors
Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Laura De Marinis
Keywords: everolimus, prrt
#1012 Efficacy of Lanreotide Autogel in MEN1-Related Gastrinoma: A Case Series
Introduction: GEP NETs, especially gastrinomas, occur in 40-70% of MEN1 patients and represent the main cause of death in these patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Laura De Marinis
Keywords: MEN1, SSA, gastrin
#1907 Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study
Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: md Sabrina Chiloiro
Keywords: pNETs, MEN, prognosis